A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1023 participants.
Also called NCT06534411
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,023 participants
- Sponsor
- Registry
-
NCT06534411
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Brazil, Canada, Germany, Greece, Hungary, India, Israel, Poland, Romania, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT06534411. Randomized; no masking; primary purpose treatment. Start 2024-11-05 (actual); primary completion 2026-06-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Acronym
- REIMAGINE 5
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Tirzepatide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06534411- Content hash
d9db9a0aa358ea9cb7682687b62f0f7c5fef7139552abfd6633db87c0348a5f9